Flavopiridol and Imatinib Mesylate in Treating Patients With Hematologic Cancer

You may be eligible if

• DISEASE CHARACTERISTICS:
• Diagnosis of 1 of the following:
• * Chronic or accelerated phase chronic myelogenous leukemia (CML) with 1 of the following:
• * Hematologic progression during prior imatinib mesylate treatment
• * Less than a complete hematologic response after at least 3 months of prior imatinib mesylate treatment
• * Less than a major cytogenetic response after at least 6 months of imatinib mesylate treatment (cytogenetic response documented by karyotype or fluorescence in situ hybridization \[FISH\])
• * Blastic phase CML\*
• * Acute lymphoblastic leukemia\*
• * Acute myeloid leukemia\* NOTE: \*Patients may be enrolled at presentation, in remission, or upon relapse
• Bcr/Abl+ in bone marrow confirmed by karyotype or FISH
• No known CNS malignancy
• PATIENT CHARACTERISTICS:
• Age
• 18 and over
• Performance status
• ECOG 0-2
• Life expectancy
• Not specified
• Hematopoietic
• See Disease Characteristics
• Hepatic
• Bilirubin no greater than 1.5 times upper limit of normal (ULN)
• AST and ALT no greater than 2.5 times ULN (5 times ULN if hepatic involvement suspected \[stratum 2 only\])
• Renal
• Creatinine no greater than 2 times ULN
• Cardiovascular
• No symptomatic congestive heart failure
• No unstable angina pectoris
• No cardiac arrhythmia
• Other
• Not pregnant or nursing
• Fertile patients must use effective contraception during and for 3 months after study participation
• No prior allergic reaction attributed to compounds of similar chemical or biological composition to study agents
• No other concurrent uncontrolled medical illness
• No ongoing or active infection
• No psychiatric illness or social situation that would preclude study participation
• PRIOR CONCURRENT THERAPY:
• Biologic therapy
• No concurrent filgrastim (G-CSF), sargramostim (GM-CSF), or interleukin-2 during the first course of study therapy unless clinically indicated for management of febrile neutropenia or thrombocytopenia
• Concurrent epoetin alfa allowed if started before study entry and it remains clinically appropriate
• Chemotherapy
• Not specified
• Endocrine therapy
• Not specified
• Radiotherapy
• Not specified
• Surgery
• Not specified
• Other
• See Disease Characteristics
• Recovered from all prior therapy
• No other concurrent investigational or anticancer agents
• No concurrent combination antiretroviral therapy for HIV-positive patients